With Eli Lilly up by a stunning 47% so far this year, many investors are likely prone to feeling they're stuck on the sidelines after this bull run. Even if there's plenty of upside left -- and in Eli Lilly's case, there almost certainly is -- it can still feel safer to find another company that looks to have good times ahead rather than buying shares of yesterday's winner.

There's no foolproof way of determining which businesses are going to see their shares soar, but, at least in biotech, clinical catalysts are a good indicator as to when there might be a big move. And, as watchers of Eli Lilly know, companies attempting to develop new weight loss drugs are in vogue right now.

So with that framing, let's examine a pair of healthcare stocks that look ready to run thanks to the catalysts they have lined up.

Continue reading

Source Fool.com